Novo Nordisk study finds Wegovy ingredient reduces child obesity
A Novo Nordisk study shows semaglutide reduces body mass index in children aged 6 to 12.
2026年11月17日
/ DANGDI / DANGDI / DANGDI /Novo Nordisk announced that its weight-loss drug ingredient helps children with severe obesity.
The active ingredient semaglutide is used in the Danish company’s drug Wegovy.
In Denmark, doctors can currently prescribe Wegovy to children aged 12 and older.
The new STEP Young study tested children between 6 and 12 years old.
Participants received weekly semaglutide injections alongside a calorie-reduced diet and more physical activity.
After 68 weeks, children on semaglutide saw their average BMI drop by 17.4 percent.
In contrast, children in the placebo group saw their BMI rise by 2.2 percent.
Furthermore, 40.4 percent of treated children were no longer classified as severely obese.
No children in the placebo group achieved this improvement.
Martin Holst Lange from Novo Nordisk emphasized that childhood obesity causes lifelong consequences.
The study included 167 children and ran from July 2023 to July 2026.
Researchers published these findings in the New England Journal of Medicine.
This report was originally published by CPH Post.
Source: The Copenhagen Post

